Clinical Trial Update: A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of GDC-0917 in patients with refractory solid tumors or lymphoma has completed. The study assessed safety, tolerability, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• GDC-0917

Snippet

Sponsor: Genentech, Inc. | Conditions: Solid Cancers | Phase 1 | Status: COMPLETED